OBJECTIVE： To investigate the information labeling for “Drug-ethanol interaction （DEI）” in drug package inserts of our hospital， to provide guidance for clinical rational drug use. METHODS： Collected 1 587 prescriptions for use in our hospital in 2017. DEI of drug package inserts were analyzed statistically according to Drug Pakcge Inserts and Label Management Regulation， Regulations for Chemical Drugs and Biological Products for Treatment. RESULTS： There were 131 drug package inserts containing DEI information， including 69 oral dosage forms， 57 injection forms and 5 external dosage forms. The drug package inserts without any DEI warning remarks account for 91.75％ of the total statistics. The information labeling for DEI was dispersed in multiple projects， mainly tagged in the term of “Drug Interaction” and “Precautions”， 71.76％ and 21.37％ respectively. In the DEI warning remarks， its effect on the use of drugs in various systems includes the endocrine system， cardiovascular system

and central nervous system. CONCLUSIONS： It is suggested that the relevant departments should add “DEI” in the specification of drug package inserts and standardize the labeling content of DEI， including whether DEI will affect therapeutic efficacy of drugs， potential safety problems warning of DEI； it provides accurate DEI information for drug users and avoids the occurrence of ADR.